Colchicine may not lessen Covid-19 severity
Colchicine, an anti-inflammatory drug normally used to treat gout, doesn’t lessen Covid-19 severity or stave off the risk of death in hospital patients. It is also associated with a high risk of side effects, according to research published in RMD Open.
Early observational studies had suggested that colchicine might be a useful Covid-19 treatment, but the new research concludes: “Colchicine does not reduce the risk of mortality, need for ventilatory support, intensive care unit admission or length of hospital stay among patients with Covid-19.”
The researchers do say, however, that their findings should be interpreted cautiously due to the inclusion of open labelled randomised clinical trial data.
Identify the 5 key elements to address in your dry skin consultations
This module will improve your hay fever knowledge, helping you to understand its impact on sufferers and recommend the right products to ease symptoms